Latest Clinical & Research News
Specialty: Heart & Vascular
Behnood Bikdeli, MD, MS, at Brigham and Women’s Hospital, and team reported favorable longer-term catheter-directed thrombolysis (CDT) results for pulmonary embolism. In a randomized clinical trial, they observed a more durable effect of CDT plus anticoagulation than with anticoagulation monotherapy on several metrics.
Read More...
Researchers at Brigham and Women’s Hospital have developed a stretchable double-network hydrogel bioink system for microfluidic bioprinting of small-diameter vascular conduits. They say the conduits recapitulate the structural and biological functions of native blood vessels.
Read More...
In the first large, population-based cohort study of the issue, researchers at Brigham and Women’s Hospital found 22% of eligible patients declined statin therapy initially and 6% never accepted the recommendation. Results on both measures were significantly higher for women than men.
Read More...
The Brigham’s Anand Vaidya, MD, MMSc, and Jenifer Michelle Brown, MD, have led studies showing that primary aldosteronism (PA) is much more prevalent than assumed—and may be a causative mechanism for 15%–24% of primary hypertension cases. Now, they are expanding PA screening among high-risk patient populations.
Read More...
Cardiovascular experts from Brigham and Women’s Hospital will present their latest research and clinical advancements at this year’s American College of Cardiology Scientific Session & Expo on March 4 – 6, 2023, held virtually and in-person in New Orleans, LA.
Read More...
Hydroxychloroquine and chloroquine (HCQ/CQ) have known cardiovascular adverse effects. However, Brigham and Women’s Hospital researchers found that before the COVID-19 pandemic, electrocardiograms were infrequently obtained prior to initiation of HCQ/CQ and even less often during follow-up.
Read More...
Researchers at Brigham and Women’s Hospital conducted the first randomized, active comparator trial to explore the effect of disease-modifying anti-rheumatic drugs on vascular inflammation in rheumatoid arthritis.
Read More...
In this clinical trial, investigators at Brigham and Women’s Hospital found that although pemafibrate therapy was associated with reduced plasma triglyceride levels and certain other lipids, it did not reduce the risk of cardiovascular events.
Read More...
Marc S. Sabatine, MD, MPH, Michelle L. O’Donoghue, MD, MPH, and colleagues completed the phase 2 dose-finding OCEAN(a)-DOSE trial of olpasiran. They report that olpasiran was associated with dose-dependent reductions in lipoprotein(a), with decreases of more than 95% when administered every 12 weeks.
Read More...
In this Medical Grand Rounds presentation, Naomi D.L. Fisher, MD, of Brigham and Women’s Hospital, joined a panel of colleagues from the Boston area to discuss recent developments in the diagnosis and treatment of hypertension among older adults.
Read More...